MGC Diagnostics Corporation to Report Third Quarter Fiscal 2013 Financial Results on Thursday, August 29, 2013

  MGC Diagnostics Corporation to Report Third Quarter Fiscal 2013 Financial
                     Results on Thursday, August 29, 2013

PR Newswire

SAINT PAUL, Minn., Aug. 20, 2013

SAINT PAUL, Minn., Aug. 20, 2013 /PRNewswire/ -- MGC Diagnostics Corporation
(NASDAQ: MGCD), a global medical technology company, today scheduled a
conference call to discuss its financial results for the third quarter of
fiscal year 2013, ended July 31, 2013. The call will be at 4:30 p.m. ET on
Thursday, August 29, 2013. The Company will report financial results for the
third quarter of fiscal year 2013 after the markets close on Thursday, August
29, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

Participants can dial (877) 317-6789 or (412) 317-6789 to access the
conference call, or listen via a live Internet webcast on the Company's
website at www.mgcdiagnostics.com. A replay of the conference call will be
available by dialing (877) 344-7529 or (412) 317-0088, confirmation code
10032923, through September 4, 2013. A webcast replay of the conference call
will be accessible on the Company's website at www.mgcdiagnostics.com for 90
days.

About MGC Diagnostics

MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is
a global medical technology company dedicated to cardiorespiratory health
solutions. The Company, through its subsidiary Medical Graphics Corporation,
develops, manufactures and markets non-invasive diagnostic systems. This
portfolio of products provides solutions for disease detection, integrated
care, and wellness across the spectrum of cardiorespiratory healthcare. The
Company's products are sold internationally through distributors and in the
United States through a direct sales force targeting heart and lung
specialists located in hospitals, university-based medical centers, medical
clinics, physicians' offices, pharmaceutical companies, medical device
manufacturers, and clinical research organizations (CROs). For more
information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Contact: Wesley W. Winnekins         Joe Dorame, Robert Blum, Joe Diaz
         MGC Diagnostics Corporation Lytham Partners, LLC
         Chief Financial Officer    (602) 889-9700
         (651) 484-4874             mgcd@lythampartners.com

SOURCE MGC Diagnostics Corporation

Website: http://www.mgcdiagnostics.com
 
Press spacebar to pause and continue. Press esc to stop.